Introduction In the critical landscape of pharmaceutical development, the transition from phase II (safety) to phase III (efficacy) is often described as the “valley of death”, with approximately 70% of drug development projects failing to progress further. Even for those who reach Phase III, the hurdle remains high, with 57% of failures attributed to inadequate efficacy and … [Read more...]